Healthcare -
Biotechnology - NASDAQ - US
$ 1.67
-1.76 %
$ 15.5 M
Market Cap
-0.45
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
SAB Biotherapeutics, Inc.
| Revenue | 1.32 M |
| Cost Of Revenue | 4.79 M |
| Gross Profit | -3.47 M |
| Operating Expenses | 42.9 M |
| Operating Income | -42.9 M |
| Other Expenses | -8.81 M |
| Net Income | -34.1 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Revenue | 1.3 | 2.2 | 23.9 | 60.9 | 55.2 | 3.4 |
| GROSS PROFIT | ||||||
| Cost Of Revenue | 4.8 | 3.7 | 3.3 | 1.7 | 0 | 0 |
| Gross Profit | (3.5) | (1.5) | 20.6 | 59.2 | 55.2 | 3.4 |
| OPERATING INCOME | ||||||
| Operating Expenses | 42.9 | 36.6 | 28.9 | 13.4 | 34.7 | 12.1 |
| Selling, General and Administrative Expenses | 14.0 | 20.1 | 16.4 | 17.1 | 6.8 | 4.1 |
| Research and Development Expenses | 30.3 | 16.5 | 36.4 | 57.2 | 27.9 | 8.0 |
| Operating Income | (42.9) | (38.1) | (28.9) | (13.4) | 20.6 | (8.7) |
| PRE-TAX INCOME | ||||||
| Interest Income Expense | 0.3 | 0.3 | 0.3 | 0.3 | 0.5 | 0.4 |
| Total Other Income | 8.8 | (4.1) | 10.2 | (3.8) | (0.4) | (0.3) |
| Pre-Tax Income | (34.1) | (42.2) | (18.7) | (17.1) | 20.1 | (9.0) |
| NET INCOME | ||||||
| Tax Provision | 0 | 0 | 25.6 K | 0.3 | 0.5 | 0.4 |
| Net Income | (34.1) | (42.2) | (18.7) | (17.4) | 20.1 | (9.4) |
| EPS | 3.68 | 7.64 | 4.31 | 6.38 | 7.92 | 0.22 |